IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yigal Nochomovitz - Citigroup - Analyst : So obviously, a big year coming up for you. A lot of programs. A lot of studies both early as well as mid as well as late stage. So there's a lot to absorb. So maybe just at a first blush, first question, just set the scene for everyone in terms of what to expect, what are the key readouts for 2025, how to think about the company and how to think about the mission and the thesis?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And there's even more I think that we have to get to beyond those. But let's start with the late stage. So for MUM, you mentioned the PFS at the end of the year. So assuming you achieve the similar benefit over standard of care, just give us the timelines. I mean when could this drug potentially be approved? How quickly could you file it and approved?

Question: Yigal Nochomovitz - Citigroup - Analyst : So help investors understand the reasons to be confident in a positive PFS. I mean obviously, as you pointed out, you've got a very nice separation versus standard care already. But are there other things that should be pointed out as far as why to be confident? And if there are any risks that -- obviously, there are always risks, but in terms of some things that you believe you need to watch out for to make sure the study ends up being successful? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 19, 2025 / 5:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit

Question: Yigal Nochomovitz - Citigroup - Analyst : So I mean obviously, that would be a conversation with the regulators, but is the expectation that the label would be HLA negative out of the gates, or could it be broader?

Question: Yigal Nochomovitz - Citigroup - Analyst : Now this down, the Phase 2 update that you referenced on the OS is very interesting, especially since it's coming ahead of the PFS for the Phase 3. So I mean what should be the expectations there relative to standard therapy? And assuming that looks really good, I mean I would think that that should advance or improve the chances on the PFS just because we have a hard survival endpoint. But just help frame what could happen if that OS event, which is, as you point out, we haven't seen any of that before?

Question: Yigal Nochomovitz - Citigroup - Analyst : So in other words, 18. You're looking for something in the high teens. 18 to 19 versus 12 to 13. Is that correct? Is that something --

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. All right. So let's talk about the neoadjuvant, which is obviously of great interest as well. So you mentioned you're going to have some updates in terms of the, well, two things, the 95 patients and then the final walk down of the Phase 3. So can we get into a little more detail on that? And some of that's really important as far as understanding the vision endpoint for the Phase 3. So what are we going to get in that up -- that next clinical update that will help investors get more clarity or understanding on that vision piece?

Question: Yigal Nochomovitz - Citigroup - Analyst : And then the other aspects are more or less clarified like using the disease, the metastasis-free survival if I have that right, and the BCVA.

Question: Yigal Nochomovitz - Citigroup - Analyst : And then as far as timelines there, that's as you've articulated previously, or that could potentially be modified based on further clarity with the regulators?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. So anyone, as a reminder, if there are questions, just yigalnochomovitz@citi.com, I'm happy to relay it. So let's move on and talk about some

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And the -- what is this clinical strategy going to look like? Obviously, small cell lung cancer is on the table, but that's not all there is. I mean there's a lot else in neuroendocrine which you could leverage maybe.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And then the timelines, there will be data this year for that.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. Let's talk about MAT2A. So obviously you have the combo with Gilead. So let's start with Trodelvy. Urothelial certainly makes a lot of sense for the reasons you've explained. And now non-small cell as well. So is the biology -- is the thesis there the same or is there some specific differences in terms of the reason to combine in non-small cell?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And what do you I mean, obviously, in addition to the tolerability that you mentioned, what sort of the rough sort of bar for taking the combo forward? What do you -- what would you like to see or what would Gilead like to see to quote-unquote resurrect Trodelvy and you see? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 19, 2025 / 5:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. So then obviously, you've been spinning up the engines on your own development of your own PMT 5. And you're advancing that with your 397. So talk about that, and how that that study is evolving and just, maybe very briefly touch on the the choice to to move past the Amgen compound.

Question: Yigal Nochomovitz - Citigroup - Analyst : I mean obviously, there was a very strong, the synergy data with 397 and and MG 193. Are you -- are we going to see that for clinically? I mean assume you have it already or you haven't -- I guess we haven't seen it yet, but will we see that before we get clinical data, or is it essentially going to be the same very good story again on the pre-clinical side with that combo with your PRMT5.

Question: Yigal Nochomovitz - Citigroup - Analyst : And how are you thinking about the prioritization of the combo with the original monotherapy work with 397?

Question: Yigal Nochomovitz - Citigroup - Analyst : And as far as the first combo study, are you focusing on specific tumor types or is it just going to be more of a basket study initially?

Question: Yigal Nochomovitz - Citigroup - Analyst : Yeah.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And so that study starts this half?

Question: Yigal Nochomovitz - Citigroup - Analyst : I mean, and to state the obvious, your PRMT5 is wholly owned, it's yours, so you control it, which is a key advantage. But is there anything else in terms of the molecule itself that may provide some additional benefit versus your former partner, or is it really more just about the control of the molecule?

Question: Yigal Nochomovitz - Citigroup - Analyst : I just when I heard that correctly, you do not want --

Question: Yigal Nochomovitz - Citigroup - Analyst : And the reason is just to remind everyone why because.

Question: Yigal Nochomovitz - Citigroup - Analyst : So for cancers where there would be first expected brain metastasis that you would need a different approach perhaps, or that wouldn't be the focus for this development.

Question: Yigal Nochomovitz - Citigroup - Analyst : Let's hit some of the other earlier ones and there's a few. So the Werner Helicase compound is in the clinic, is that right? And but yeah.

Question: Yigal Nochomovitz - Citigroup - Analyst : So you're going to have an update on what I understand is essentially, proof of biology and proof of of MOA and very soon, but, and then perhaps some early look in the MS MSS high patients later in the year.

Question: Yigal Nochomovitz - Citigroup - Analyst : And just remind everyone for those less familiar, I mean, Werner Hiller case is one is quote-unquote one of those holy grail targets as I understand, why is it so critical and how broad is the applicability across solid tumors? What if this if this shows POC where how broad could it be?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. Then quickly, the Pol Theta is another important one. Remind everyone what how that's different from Werner Helicase and what the the opportunity there is.

Question: Yigal Nochomovitz - Citigroup - Analyst : So they were both obviously very hard to find, as you say, the right chemical matter. Yeah. Can you talk about, I'm just curious, just this is more just, I guess for the history books, but it is still fascinating, which of these, which one did you figure out first and then did that once you solved the one, did it help you bootstrap to solve the other one faster?

Question: Yigal Nochomovitz - Citigroup - Analyst : And I mean I I think some some may just not appreciate the the level of effort in the medcam side and how deep your benches, I guess, pun intended in terms of, that that effort. Can you spend like just 30 seconds to a minute just to kind of explaining to people what what you've got and how many chemists you have and you do a lot of outsourcing too. I mean, it's quite a remarkable effort and I I don't think it's widely understood.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And then there's one more clinical asset we semi-glossed over, but we don't want to forget about the PA inhibitor, not to be confused with the par par inhibitors. So par, you've got a few studies there with with Keytruda and then with the TOPA 1 ADC. Can you just elaborate on strategy on those and again the same question on when we're going to get some POC?

Question: Yigal Nochomovitz - Citigroup - Analyst : And then the reason for the Keytruda combo is what exactly?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. So you would still -- you would advance that combo if it looks good in addition to the. Exactly, yeah, the to the to one. All right. Now then as far as pre-clinical, Was there another, I maybe have this wrong, but I thought there was yet another am mat mat to a pathway target which you were, you had somewhere in the in the discovery phase that you were looking at, is that right or?

Question: Yigal Nochomovitz - Citigroup - Analyst : So that that sounds like a target that either people know about but just have passed over since the level of difficulty is just immense, but you've solved it, or is it just not on people's radar screens or both?

Question: Yigal Nochomovitz - Citigroup - Analyst : And that one, and I mean, I know you can't really say a ton right now, but is the idea there that it would be stand-alone as a monotherapy or could you could also do a combo with your own PRMT5 or the 397. I think a triple combo may probably would not make sense, but what's the longer term thinking with that program if you can?

Question: Yigal Nochomovitz - Citigroup - Analyst : Is that does that sort of complete the triad in terms of the key targets lurking?

Question: Yigal Nochomovitz - Citigroup - Analyst : So that one doesn't have a number. I'm just looking at your PowerPoint, that one doesn't have a number yet, is that right?

Question: Yigal Nochomovitz - Citigroup - Analyst : That DC goal this year. So once we get it.

Question: Yigal Nochomovitz - Citigroup - Analyst : And then two more that are still just very quick comments on the KAT6, and then the other interesting about that is that it may have some differentiation versus friends at Pfizer, given you say you're hitting the KAT7 domain too. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 19, 2025 / 5:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And then is this the very last one that we didn't hit on was you have your own B7H3/PTK7 and I don't know much about that PTK7 target. What exactly is that? And What's the genesis of that one, and where where could it go?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. We covered a lot of territory. Did I miss anything? Becayse I want to make sure that covered all the programs. I think we got to everything, but if not, please. Let me know.